Just a moment, the page is loading...

GSK-116678




A randomised, double-blind (sponsor unblinded), placebo-controlled, parallel-group, multicentre study to evaluate the efficacy and safety of GSK2269557 administered in addition to standard of care in adult subjects diagnosed with an acute exacerbation of Chronic Obstructive Pulmonary Disease
nemiralisib
116678
NCT02294734
Pulmonary Disease, Chronic Obstructive
Phase 2
The raw data are included within the analysis-ready data for this study and are not provided separately
July 2021